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Abstract
Pterostilbene (PTE), a natural analog of resveratrol, is available both as a diet ingredient and a dietary supplement. The present
study was undertaken to assess the effect of PTE on the activity of antiepileptic drugs in the acute seizure tests in mice, i.e., the
intravenous pentetrazole (iv PTZ) seizure threshold, maximal electroshock (MES), and 6 Hz-induced psychomotor seizure tests.
Our study revealed that PTE enhanced the anticonvulsant effect of clonazepam but did not change the activity of tiagabine in the
iv PTZ test. In the MES test, PTE increased the effect of carbamazepine but did not affect the protective properties of topiramate,
while in the 6-Hz test, we noted a significant enhancement of the activity of oxcarbazepine, but there were no changes in the
activity of valproate. Interactions of PTE with carbamazepine and oxcarbazepine were pharmacokinetic, which was determined
by the increase of concentration of these antiepileptic drugs both in the serum and brain. In contrast, interactions between PTE
and clonazepam were pharmacodynamic since there were no changes in the concentration of clonazepam. Combined treatment
with carbamazepine and PTE significantly attenuated muscular strength (estimated in the grip strength test) but did not change
motor coordination (assessed in the chimney test) in mice. Other studied antiepileptic drugs and their combinations with PTE did
not change these parameters. Further studies are required to evaluate the influence of PTE on the activity of anticonvulsant drugs
to estimate the safety of using PTE by patients with epilepsy.
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Abbreviations
CBZ Carbamazepine
CZP Clonazepam
ED50 Dose which protects 50% of the tested animals from
the seizures
ip Intraperitoneally
iv Intravenously
MES Maximal electroshock
OXC Oxcarbazepine
PTE Pterostilbene
PTZ Pentetrazole
sc Subcutaneously
SEM Standard error of the mean
TGB Tiagabine
TPM Topiramate
VPA Valproate
Introduction
Pterostilbene (PTE, 3,5-dimethoxy-4′-hydroxystilbene) is a
naturally occurring polyphenol in the stilbene group which
was first isolated from red sandalwood and subsequently de-
tected in grapes, blueberries, and heartwood. It was also iden-
tified in some plants used in folk medicine for the treatment of
diabetes and cardiovascular diseases (Kosuru et al. 2016).
PTE is a natural analog of resveratrol (RES), the most popular
and known stilbenoid, which was detected in red wine and
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recognized as one of the compounds responsible for BFrench
paradox^ (Poulose et al. 2015). Compared with RES, PTE has
greater lipophilicity and higher bioavailability after oral ad-
ministration, which makes it more clinically useful
(Kapetanovic et al. 2011). Both of these compounds produce
numerous health beneficial effects, e.g., antioxidative, anti-
inflammatory, anticancer, and anti-obesity properties
(Kosuru et al. 2016).
A wide range of biological and pharmacological effects of
PTE has attracted attention from the scientific and medical
community and suggests that this compoundmight have some
beneficial effects in cardiovascular diseases, cognitive dys-
functions, and aging (Akinwumi et al. 2018). Diet supple-
mented with PTE reversed the decline of cognitive perfor-
mance in aged rats (Joseph et al. 2008). Moreover, PTE
abolished streptozotocin-induced memory impairment in rats
(Naik et al. 2017) and lipopolysaccharide-induced learning
and memory deficits in mice (Hou et al. 2014). Its anxiolytic
activity was observed in the elevated plus maze test in mice
(Al Rahim et al. 2013). Our recent study demonstrated an
anticonvulsant activity of PTE both in the zebrafish
pentetrazole (PTZ) assay and in three acute seizure tests in
mice, i.e., in the intravenous (iv) PTZ seizure threshold, max-
imal electroshock seizure threshold (MEST) and 6 Hz seizure
threshold tests (Nieoczym et al. 2019). A human clinical trial
revealed that therapy with PTE decreases both systolic and
diastolic blood pressure as well as increases low-density lipo-
protein (LDL) concentration (Riche et al. 2014). Clinical
study did not show any negative drug effects on the hepatic,
renal, and glucose markers (Riche et al. 2013).
PTE is a constituent of the human diet and is currently
accessible as a diet supplement recommended to patients with
heart diseases, high blood pressure, and diabetes. Moreover,
PTE might improve memory, reduce stress, and anxiety as
well as support weight loss (Li et al. 2018). Market accessi-
bility of PTE makes a possibility for taking it by patients with
epilepsy, also simultaneously with antiepileptic drugs. To
study the interaction between PTE and antiepileptic drugs,
we were also prompted by the results of our previous study
that demonstrated the anticonvulsant properties of PTE.
Combined treatment with antiepileptic drugs and PTE creates
an opportunity for some interactions between these com-
pounds, which might have beneficial or negative results.
Investigation of the interactions between antiepileptic drugs
and PTE is necessary to determine the safety of the studied
stilbene and to estimate potential benefits or wastes of using
PTE as an added therapy in patients with epilepsy.
The aim of the present study was to investigate the influ-
ence of PTE on the anticonvulsant activity of some antiepi-
leptic drugs in three acute seizure tests in mice, i.e., clonaze-
pam (CZP) and tiagabine (TGB) in the iv PTZ test, carbamaz-
epine (CBZ), and topiramate (TPM) in the maximal electro-
shock (MES) test, valproate (VPA) and oxcarbazepine (OXC)
in the 6 Hz-induced psychomotor seizure test. For each test we
selected two drugs—one medicine from the first generation
(i.e., CZP, CBZ and VPA) and one second-generation drug
(i.e., TGB, TPM, and OXC), which are characterized by a
high effectiveness in inhibiting convulsions induced in a given
model (Barton et al. 2001; Löscher and Schmidt 2011).
Additionally, total brain and free serum concentrations of
CZP, CBZ, and OXC were determined to define the kind of
their pharmacological interaction with PTE. Influence of the
studied antiepileptic drugs and their combinations with PTE
on the motor coordination and muscular strength in mice were
estimated in the chimney and grip strength tests, respectively.
Material and Methods
Animals
Male Swiss mice weighing 23–28 g were obtained from a
licensed breeder (Laboratory Animals Breeding, Słaboszów,
Poland) and used in the study after at least 1 week of acclima-
tization. The animals were housed in the polycarbonate cages
under strictly controlled conditions (ambient temperature 21–
24 °C, relative humidity 45–65%, a 12/12 light/dark cycle
with the light on at 6:00 a.m.) with unlimited access to chow
pellets and tap water. All experiments were performed at the
same time of day (between 8:00 a.m. and 3:00 p.m.) to min-
imize circadian influences. Control and drug experiments
were always done on the same day to avoid day-to-day vari-
ations in convulsive susceptibility. Each mouse was used only
once. All procedures were conducted in accordance with the
European Union Directive of 22 September 2010 (2010/63/
EU) and Polish legislation acts concerning animal experimen-
tations. The experimental procedures and protocols were ap-
proved by the Local Ethics Committee in Lublin (License No.
18/2018).
Drugs
The following drugs were used: PTE (Toronto Research
Chemicals INC, Toronto, ON, Canada), CZP (Clonazepamum,
Polfa, Warszawa, Poland), TGB (Gabitril, Sanofi Winthrop,
Gentilly, France), CBZ (kindly donated by Polpharma S.A.,
Starogard Gdański, Poland), TPM (Topiran, Ranbaxy,
Warszawa, Poland), VPA (as sodium salt; Sigma-Aldrich Co.,
St. Louis, MO, USA), and OXC (Trileptal, Novartis Pharma
GmbH, Nümberg, Germany). VPA was dissolved in saline,
while the remaining drugs were suspended in a 5% solution of
Tween 80 (POCH, Gliwice, Poland) in normal saline. All the
used solutions/suspensions were administered intraperitoneally
(ip) at a constant volume of 10 ml per kg body weight. VPA and
TGB were injected 15 min before the respective experimental
procedure, PTE, CBZ, OXC, and CZP 30 min, while TPM
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60 min before the tests. The pretreatment times for PTE and the
studied antiepileptic drugs were taken from the literature and
confirmed in our previous studies (Nieoczym et al. 2010,
2013, 2019).
The Timed iv PTZ Test
Mice were placed in the cylindrical restrainer, and the needle
(27 G, 3/4 in., Sterican®, B. Braun Melsungen AG,
Melsungen, Germany) was inserted into the lateral tail vein.
Correct location of the needle was validated based on the
appearance of the blood in the drain and, to avoid its displace-
ment, the needle was stuck by a piece of adhesive tape to the
tail. The needle was attached by the polyethylene drain
(PE20RW, Plastic One Inc., Roanoke, VA, USA) with the
syringe which was filled with 1% solution of PTZ (Sigma-
Aldrich, St. Louis, MO, USA) in water and put in the infusion
pump (model Physio 22, Hugo Sachs Elektronik–Harvard
Apparatus GmbH, March-Hugstetten, Germany). The sy-
ringe pump infused the PTZ solution into the vein at a con-
stant rate of 0.2 ml/min. Following the injection, mice were
taken out from the restrainer and placed individually in the
Plexiglas box for observation. During the infusion of PTZ
solution into the vein of freely moving animals, three sei-
zure types sequentially appeared, i.e., the first myoclonic
twitches, generalized clonus with loss of righting reflex,
and forelimb tonic extension. The infusion of PTZ was
stopped immediately after the onset of the tonic seizures,
which usually were lethal. If an animal survived the test, it
was euthanized immediately. Time intervals from the start
of infusion to the appearance of the three separate types of
seizures were noted, and the threshold doses of PTZ (in
mg/kg body weight) for each type of seizures were calculat-
ed according to the following formula:
PTZ mg=kgð Þ ¼ infusion duration sð Þ  infusion rate ml=sð Þ  PTZ concentration mg=mlð Þ
weight kgð Þ
Experimental groups consisted of 9–13 animals. The data
obtained in the iv PTZ test are presented as the mean threshold
dose of PTZ (in mg/kg) ± standard error of the mean (SEM)
needed to elicit the respective endpoint. The data were ana-
lyzed by a one-way analysis of variance (ANOVA) followed
by the Tukey post hoc test. Statistical significance was noted
when a p value was equal to or less than 0.05.
The Maximal Electroshock Seizure Test
TheMES test was carried out to evaluate the influence of PTE
on the anticonvulsant activity of CBZ and TPM. This test
allows the estimation of the median effective doses (ED50;
the dose which protects 50% of the tested animals form the
seizures) of the studied antiepileptic drugs. Animals (3–5
groups; 8 animals/group) were treated with increasing doses
of the respective antiepileptic drug or its combinations with
PTE, and they were subjected to the stimulation. Stimuli
(25 mA, 0.2 s, 50 Hz) were generated by a constant current
stimulator (Rodent Shocker, Type 221; Hugo Sachs
Elektronik, Freiburg, Germany) and delivered by saline-
soaked transcorneal copper electrodes. Before the stimulation,
1% solution of tetracaine hydrochloride was applied into an-
imals’ eyes for local anesthesia. During the stimulation, ani-
mals were restrained manually, and immediately after the
stimulation, they were placed in the Plexiglas box for obser-
vation. The endpoint in the test was the maximal
electroconvulsion which was defined as an extension of the
hindlimbs above a 90° angle to the torso of the animal. The
percentage of animals protected from the tonic hindlimb ex-
tension was noted, and ED50 doses (in mg/kg) of the tested
antiepileptic drugs were calculated according to the log-probit
method (Litchfield and Wilcoxon 1949).
The respective ED50 values were compared with one-way
ANOVA followed by the Tukey post hoc test.
The 6 Hz Psychomotor Seizure Test
Psychomotor (limbic) seizures were induced by transcorneal
supramaximal stimulation (6 Hz, 0.2 ms rectangular pulse, 3 s
duration) generated by a Grass S48 stimulator coupled with a
constant current unit CCU1 (both from Grass Technologies,
WestWarwick, RI, USA). To evaluate the influence of PTE on
the anticonvulsant potential of VPA or OXC, groups of ani-
mals (3–5 groups, 8 animals/group) were treated with increas-
ing doses of the respective antiepileptic drug or its combina-
tions with PTE and stimulated with the fixed supramaximal
current intensity of 32 mA. Before stimulation, a drop of oc-
ular anesthetic, 1% tetracaine hydrochloride solution, was ap-
plied into the animals’ corneas. The electrodes were soaked in
saline to ensure good electrical contact. During the stimula-
tion, animals were restrained manually and immediately after
the stimulation were placed in a Plexiglas box for observation
of presence or absence of the psychomotor seizures. These
seizures were characterized by immobilization or stun, often
associated with rearing, forelimb clonus, twitching of vibris-
sae, and elevated tail (Straub-tail), lasting at least 10 s from the
stimulation. Lack of the above symptoms or their cessation
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within 10 s from the stimulation was considered as absence of
seizure activity. Percentage of animals protected from convul-
sive activity was noted to determine ED50 doses. As in the
MES test, the log-probit method (Litchfield and Wilcoxon
1949) was used to determine ED50 doses of the studied drugs.
One-way ANOVA followed by the Tukey post hoc test was
used to compare the respective ED50 values, and p value equal
to or less than 0.05 was considered statistically significant.
The Grip-Strength Test
Effect of the studied antiepileptic drugs and their combina-
tions with PTE on the skeletal muscles strength in mice was
determined in the grip strength test (Meyer et al. 1979). The
apparatus (BioSeb, Chaville, France) consisted of a steel wire
grid (8 × 8 cm) connected to an isometric force transducer.
Each mouse was lifted by the tail and allowed to grasp the
grid with its forepaws and then it was gently pulled backward
until it released the grid. The maximal force in newtons (N)
exerted by a mouse before leaving the grid was recorded. The
mean of three consecutive measurements for each animal was
calculated and normalized to body weight (mN/g).
Experimental groups consisted of 10–12 animals. Results
obtained in the grip-strength test were compared using one-
way ANOVAwith the Tukey post hoc test.
The Chimney Test
The chimney test (Boissier et al. 1960) was performed to
evaluate the influence of the studied antiepileptic drugs and
their combinations with PTE on motor coordination in mice.
During the test, mice had to climb backwards up the plastic
transparent cylinder (inner diameter 3 cm and length 30 cm)
with a coarse inner surface, which was positioned vertically.
The inability of the mice to escape from the cylinder within
60 s was considered as motor impairment. Results obtained in
the test were presented as the percentage of impaired mice in
groups of 10–12 animals and were compared with the Fisher
exact probability test.
Determination of Serum and Total Brain
Concentration of CZP
The concentration of CZP was determined in serum and brain
tissue with modification of a method published by Gu et al.
(2009). The 150 μl of the homogenized sample was spiked the
10 μl of internal standard solution (CZP-D4, 1 μg/ml). The
analyte was extracted with 150 μl of acetonitrile and methanol
solution (1:1, v:v). The sample was vortex mixed (1 min,
Heidolph vortex, Germany) and centrifuged (14,800 rpm,
Sigma ultra-centrifuge, Germany). Next, 150 μl of superna-
tant was transferred to an autosampler vial and diluted with
150 μl of 0.1% formic acid solution. The 15 μl of sample was
injected on the LC-MS/MS system—Agilent 1200 chromato-
graph (Germany) coupled with Sciex API 4000 tandem mass
spectrometer (Canada). The chromatographic separation was
performed with Synergy RP-Polar column (75 × 2.0mm,
4.0 μm, Phenomenex, USA) coupled with C18 precolumn
(SecurityGuard, Phenomenex, USA). The flow rate of the
mobile phase BA^ (methanol 0.1% HCOOH (5:95, v:v) and
BB^ (methanol:0.1%HCOOH (95:5, v:v) was 0.3 ml/min. The
following elution gradient was applied: 0.0–2.5 min (60%A);
2.0–2.5 min (10% A); 2.5–5.0 min (10% A), 5.0–5.5 min
(60%A), 5.5–10 min (60% A). The total run time was
10 min. The oven temperature was 40 °C.
The mass spectrometer, equipped with an electrospray
(positive mode), has detected the ions with multiple reaction
monitoring (MRM) modes. For the CZP, the following tran-
sitions were used: 316.1→ 270.2; 316.1→ 241.1; 316.1→
214 and for CZP-D4: 320.1→ 274.1.
The retention time of the analytes was 6.4 min. The quan-
titative analysis was performed with the matrix-matched cali-
bration curve (the ratio of the CZP peak areas of the internal
standard versus drug concentrations and were linear in the
tested concentration range). The limit of quantitation of CZP
in serum and brain was 3.3 ng/ml and 0.66 ng/ml respectively.
The relative error for accuracy and the coefficient of variation
for precision were less than 10%.
Determination of Serum and Total Brain
Concentration of CBZ and OCX
In order to determine CBZ and OXC concentrations, 100 μl of
serum sample diluted with 100 μl of water or 200 μl of brain
homogenate (1:4, w/v) in water were spiked with 10 μl of
respective internal standards (IS): carbamazepine (10 μg/ml)
for oxcarbazepine and butabarbital (50 μg/ml) for
oxcarbazepine. To brain homogenate, 0.2 ml NaCl solution
(10 g/100 ml) was added, and the samples were vortexed for
15 s. Subsequently, 1 ml aliquots of extraction solvent (dichlo-
romethane for carbamazepine and ethyl acetate for
oxcarbazepine) were added to both serum samples and brain
homogenates and were vigorously shaken for 20 min (IKA
VXR Vibrax, Germany). After centrifugation (Abbott
Laboratories, USA), the organic layers of brain samples were
transferred into conical tubes and were evaporated to dryness
at 37 °C under a stream of nitrogen. The organic layers sepa-
rated from serum samples containing OXC were washed with
1 ml of 1 M HCl before evaporation. The residues were dis-
solved in 100 μL of methanol (carbamazepine) or acetonitrile
(oxcarbazepine), and 5 μL of these solutions were injected
into the HPLC system. The HPLC system (Merck Hitachi,
Darmstadt, Germany) consisted of an L-7100 isocratic pump,
an L-7200 autosampler, and a UV variable-wavelength
K-2600 detector (Knauer, Berlin, Germany). D-7000 HSM
software was used for data acquisition and processing. The
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analysis was performed on a LiChrospher® 100RP-18 col-
umn (250 × 4 mm, 5 μm) coupled with a LiChroCART guard
column (4.0 × 4.0 mm) (Merck, Germany) with the same
packing material. The mobile phase consisting of acetonitrile
and water mixed at a ratio of 34:66, v/v for carbamazepine and
36:64, v/v for oxcarbazepine was pumped at a flow rate of
1 ml/min. Chromatographic analyses were carried out at room
temperature, and the analytical wavelength was 210 nm. The
retention times of OXC and IS were approximately 5.8 and
9.1 min, whereas those of CBZ and IS were 11.3 and 6.2 min,
respectively. The calibration curves were constructed by plot-
ting the ratio of the peak areas of the studied drugs to their
respective IS versus drug concentrations, and they were linear
in the tested concentration range. The relative error for accu-
racy and the coefficient of variation for precision were less
than 10%. No interfering peaks were observed in the blank
serum or brain homogenate, and PTE did not interfere with the
assay.
Results
Influence of PTE on the Anticonvulsant Activity of CZP
and TGB in the iv PTZ Test
Figure 1a shows the effect of CZP (at a dose of 0.04 mg/kg)
and its combinations with PTE (at doses ranging from 25 to
100mg/kg) on threshold for the first myoclonic twitches in the
iv PTZ test in mice (one-way ANOVA F(4,54) = 42.60,
p < 0.0001). In groups of animals treated with CZP alone
and its combinations with PTE, thresholds for these seizures
were significantly higher than in the control (5% Tween-treat-
ed) group (p < 0.001). Additionally, statistical analysis re-
vealed that anticonvulsant effect of CZP was significantly
potentiated by PTE at a dose of 50 and 100 mg/kg (p < 0.01
and p < 0.001 vs. CZP-treated group, respectively).
Both CZP alone and its combinations with PTE significant-
ly increased generalized clonic seizure thresholds in compar-
ison with the control (5% Tween-treated) group (Fig. 1b; one-
way ANOVA F(4,48) = 16.99, p < 0.0001). Statistically sig-
nificant differences were also noted between groups of ani-
mals injected with a combination of CZP and PTE at doses of
50 and 100 mg/kg and a group of animals which received an
injection of CZP alone (p < 0.05).
Effect of CZP and its combinations with PTE on the thresh-
old for the onset of forelimb tonus in the iv PTZ test in mice is
shown in Fig. 1c (one-way ANOVA F(4,48) = 11.02,
p < 0.0001). A statistically significant increase in tonic seizure
thresholds in comparison to the control (5% Tween-treated)
group was noted both in the group treated with CZP alone and
groups injected with a combination of this antiepileptic drug
with PTE. Furthermore, PTE administered at a dose of
100 mg/kg significantly enhanced the anticonvulsant effect
of CZP (p < 0.01) against tonic seizures.
Influence of TGB administered at a dose of 5 mg/kg as well
as its combinations with PTE at doses ranging from 25 to
100 mg/kg on the seizure thresholds in the iv PTZ test in mice
are presented in Fig. 1 d–f. Both TGB alone and its combina-
tions with PTE increased the thresholds for the first myoclonic
twitch (one-way ANOVA F(4,50) = 15.13, p < 0.0001), gen-
eralized clonic seizures with loss of righting reflex (one-way
ANOVA: F(4,52) = 13.49, p < 0.0001), and tonic forelimb ex-
tension (one-way ANOVA F(4,47) = 12.05, p < 0.0001) in
comparison to the control (5% Tween-treated) group.
However, statistical analysis did not reveal significant differ-
ences between groups which were treated with TGB alone and
groups which were injected with a combination of this drug
with PTE (p > 0.05).
Influence of PTE on the Anticonvulsant Activity of CBZ
and TPM in the MES Test
Effect of PTE on the anticonvulsant activity of CBZ and TPM
in the MES test in mice is presented in Fig. 2.
One-way ANOVA (F(3,68) = 9.70, p < 0.0001) revealed a
statistically significant influence of PTE on the protective ac-
tivity of CBZ in the MES test (Fig. 2a). ED50 value of CBZ in
the control group was 11.66 ± 0.61 mg/kg, while in the group
which was cotreated with PTE at a dose of 50 mg/kg was
reduced to 7.83 ± 0.86 mg/kg (p < 0.01). The highest tested
dose of PTE, i.e., 100 mg/kg, decreased ED50 value of CBZ
by ~50% (p < 0.0001).
PTE at doses ranging from 25 to 100 mg/kg did not signif-
icantly influence the anticonvulsant activity of TPM in the
MES test in mice (Fig. 2b, one-way ANOVA F(3,68) = 1.16,
p = 0.333).
Influence of PTE on the Anticonvulsant Activity
of VPA and OXC in the 6 Hz Test
Effect of PTE (at doses of 25–100 mg/kg) on the anticonvul-
sant activity of VPA in the 6 Hz test is depicted in Fig. 3a.
Although one-way ANOVA revealed statistically significant
changes between experimental groups (one-way ANOVA
F(3,69) = 4.43, p = 0.007), there were no statistically signifi-
cant differences between control (VPA-treated) group and
groups of animals which were injected with combinations of
this antiepileptic drug with PTE.
PTE significantly enhanced the protective properties of
OXC in the 6 Hz test in mice (Fig. 3b; one-way ANOVA
F(3,68) = 5.31, p = 0.002). ED50 value of OXC in the control
group was 17.61 ± 1.36mg/kg, while in the group that was co-
administered with OXC and PTE at a dose of 100 mg/kg was
reduced to 9.02 ± 1.54 mg/kg (~49%).
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Effect of the Studied Antiepileptic Drugs and their
Combinations with PTE in the Chimney Test
and Grip-Strength Test
Influence of the studied antiepileptic drugs and their combi-
nations with PTE on the skeletal muscles strength and motor
coordination in mice is presented in Table 1.
A statistically significant decrease in muscles strength
was noted in the group of animals treated with a combina-
tion of CBZ (5.9 mg/kg) and PTE (100 mg/kg) (Tukey’s test
p < 0.05 both vs. 5% Tween-treated and CBZ-treated
groups, Table 1 part C). The remaining antiepileptic drugs
and their combinations with PTE did not statistically affect
the strength of muscles in mice.
In addition, antiepileptic drugs at the studied doses and
their combinations with PTE did not significantly influence
motor coordination in the chimney test in mice (p > 0.05).
Effect of PTE on the Serum and Total Brain
Concentrations of CZP, CBZ, and OXC
Effect of PTE on the serum and total brain concentrations of
CZP, CBZ, and OXC (antiepileptic drugs which activity was
changed by PTE in seizure tests) is presented in Table 2.
PTE administered at a dose of 100 mg/kg changed neither
serum nor total brain concentration of CZP (Table 2 part A).
Co-administration of PTE at a dose of 100 mg/kg with CBZ at
a dose of 5.9 mg/kg significantly increased both serum and
Fig. 1 Effect of PTE on the
anticonvulsant activity of CBZ
(a–c) and TGB (d–f) in the iv PTZ
seizure threshold test in mice.
TGB was administered 15 min,
while CZP and PTE were injected
30 min before the iv PTZ test. All
the drugs were administered ip at
a constant volume of 10 ml per kg
body weight. Animals in the
negative control groups received
vehicle (5% Tween 80). Each
experimental group consisted of
9–13 animals. Data are presented
as the mean threshold dose of
PTZ (in mg/kg body weight) +
SEM and were analyzed using
one-way ANOVA (CZP first
myoclonic twitch F(4,54) =
42.60, p < 0.0001; generalized
clonic seizures F(4,48) = 16.99,
p < 0.0001; forelimb tonic
extension F(4,48) = 11.02,
p < 0.0001; TGB: first myoclonic
twitch F(4,50) = 15.13,
p < 0.0001; generalized clonic
seizures F(4,52) = 13.49,
p < 0.0001; forelimb tonic
extension F(4,47) = 12.05,
p < 0.0001) with the Tukey post
hoc test. *p < 0.05, **p < 0.01,
***p < 0.001 vs. the negative
control (5% Tween-treated)
group; #p < 0.05, ##p < 0.01,
###p < 0.001 vs. CZP-treated
group. CZP, clonazepam; PTE,
pterostilbene; PTZ, pentetrazole,
TGB, tiagabine
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total brain concentrations of CBZ (Table 2 part B). Similarly,
PTE at a dose of 100 mg/kg significantly raised the level of
OXC in serum as well as in the brain (Table 2 part C).
Discussion
PTE has recently attracted much attention due to a wide variety
of biological and pharmacological properties determined both
in preclinical and clinical studies. Among numerous beneficial
effects, its influence on the central nervous system related pro-
cesses was also noted. PTE improves memory and cognition
processes (Hou et al. 2014; Naik et al. 2017) and showed
anxiolytic activity (Al Rahim et al. 2013) in animal models.
Additionally, we showed the anticonvulsant activity of PTE in
the zebrafish PTZ assay and three acute seizure threshold tests
in mice, i.e., in the iv PTZ, MEST, and 6 Hz psychomotor
seizure tests (Nieoczym et al. 2019). In our present study, we
investigated the influence of PTE on the activity of some anti-
epileptic drugs in these seizure tests. Although results of mu-
rine studies could not be directly transferred to the clinical
practice, our results could serve as an indication to assess the
safety of using PTE by patients treated with antiepileptic drugs
and whether it could be used as add-on therapy.
In our study, we used three different seizure tests which
allowed us to analyze the influence of PTE on the action of
some antiepileptic drugs in relation to different kinds of sei-
zures. The iv PTZ test is considered a model of generalized
absence seizures (Mandhane et al. 2007), the MES test corre-
sponds to the generalized tonic-clonic convulsions (Castel-
Branco et al. 2009), while the 6 Hz test was described as a
model of psychomotor seizures (Barton et al. 2001) in
humans. All of these tests are widely used in the preclinical
study of compounds with potential antiepileptic properties.
Our results demonstrated that PTE significantly enhanced
the anticonvulsant action of CZP in the iv PTZ test, CBZ in
Fig. 3 Effect of PTE on the anticonvulsant activity of VPA (a) and OXC
(b) in the 6 Hz psychomotor seizure test in mice. VPAwas administered
15 min, while PTE and OXC 30 min before the 6 Hz test. All the drugs
were administered ip at a constant volume of 10 ml per kg body weight.
Animals in the control group received antiepileptic drug (VPA or OXC)
alone, while other experimental groups received the respective
antiepileptic drug in combination with PTE. Data are presented as ED
doses (the doses which protect 50% of the tested animals from the
psychomotor seizures) + SEM and were analyzed using one-way
ANOVA (VPA F(3,69) = 4.43, p = 0.007; OXC F(3,68) = 5.31, p =
0.002) with the Tukey post hoc test. **p < 0.01 vs. control (OXC-
treated) group. OXC, oxcarbazepine; PTE, pterostilbene; VPA, valproate
Fig. 2 Effect of PTE on the anticonvulsant activity of CBZ (a) and TPM
(b) in the MES test in mice. PTE and CBZ were administered 30 min,
while TPM 60 min before the MES test. All the drugs were administered
ip at a constant volume of 10 ml per kg body weight. Animals in the
control group received antiepileptic drug (CBZ or TPM) alone, while
other experimental groups received the respective antiepileptic drug in
combination with PTE. Data are presented as ED doses (the doses which
protect 50% of the tested animals from the maximal electroshock
convulsions) + SEM and were analyzed using one-way ANOVA (CBZ
F(3,68) = 9.70, p < 0.0001; TPM F(3,68) = 1.16, p = 0.333) with the
Tukey post hoc test. **p < 0.01, ***p < 0.001 vs. control (CBZ-treated)
group. CBZ, carbamazepine; PTE, pterostilbene, TPM, topiramate
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the MES test, and OXC in the 6 Hz-induced psychomotor
seizure model in mice. There was no statistically significant
influence of PTE on the anticonvulsant properties of TGB,
TPM, and VPA in the respective experimental models.
Using combinations of some drugs or drugs and diet supple-
ments, which are often taken without medical recommendation
and may not be reported to physicians, gives an opportunity to
produce pharmacological interactions with both beneficial and
harmful effects in clinical response. Unwanted effects might in-
clude a reduction in therapeutic effects of the drug as well as
worsen and/or induction of some side effectswhichmight lead to
treatment discontinuation. Pharmacological interactions of drugs
may have pharmacokinetic or pharmacodynamic character.
Pharmacodynamic interactions concern changes in drug activity
Table 1 Influence of the studied
antiepileptic drugs and their
combinations with PTE on the
muscular strength and motor
coordination in mice
Treatment (mg/kg) Neuromuscular strength (mN/g) Impairment of motor
coordination (%)
N
A
Control (5% Tween) 28.80 ± 1.1 0 12
CZP (0.04) 28.31 ± 1.6 0 12
CZP (0.04) + PTE (25) 26.25 ± 1.1 0 11
CZP (0.04) + PTE (50) 27.71 ± 0.9 0 12
CZP (0.04) + PTE (100) 27.99 ± 1.2 0 12
One-way ANOVA F(4,54) = 0.604, p = 0.661
B
Control (5% Tween) 29.09 ± 1.8 0 12
TGB (5) 29.18 ± 0.9 0 12
TGB (5) + PTE (25) 29.37 ± 0.9 9 11
TGB (5) + PTE (50) 28.66 ± 1.1 8 12
TGB (5) + PTE (100) 28.23 ± 0.9 0 12
One-way ANOVA F(4,55) = 0.16, p = 0.958
C
Control (5% Tween) 30.60 ± 0.9 0 10
CBZ (5.9) 30.38 ± 1.1 0 10
CBZ (5.9) + PTE (100) 26.72 ± 1.1*# 10 10
One-way ANOVA F(2,27) = 4.56, p = 0.020
D
Control (5% Tween 80) 32.49 ± 0.9 0 10
TPM (29.4) 30.45 ± 1.3 0 10
TPM (29.4) + PTE (100) 31.20 ± 1.0 0 10
One-way ANOVA F(2,27) = 0.93, p = 0.409
E
Control (5% Tween) 28.53 ± 1.2 0 10
VPA (93) 28.09 ± 1.7 0 10
VPA (93) + PTE (100) 26.20 ± 1.1 0 10
One-way ANOVA F(2,27) = 0.82, p = 0.451
F
Control (5% Tween) 30.60 ± 0.9 0 10
OXC (9.02) 31.77 ± 1.5 0 10
OXC (9.02) + PTE (100) 30.48 ± 1.0 0 10
One-way ANOVA F(2,27) = 0.39, p = 0.683
VPA and TGB were administered 15 min before the tests, PTE, CBZ, OXC, and CZP, 30 min, while TPM,
60 min. Control group received the vehicle. All solutions/suspensions were injected ip. Each experimental group
consisted of 10–12 animals. Results from the grip strength test are presented as the mean ± SEM grip strengths in
millinewtons per gram of mouse body weight (mN/g) and were analyzed with one-way ANOVA followed by the
Tukey post hoc test. Data from the chimney test are presented as a percentage of animals with impairment of
motor coordination and were compared using the Fisher exact probability test. *p < 0.05 vs. control (5% Tween-
treated) group; #p < 0.05 vs. CBZ-treated group. CBZ carbamazepine, CZP clonazepam, OXC oxcarbazepine,
PTE pterostilbene, TGB tiagabine, VPA valproate
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in the area of target tissue, i.e., influence of agonist and antago-
nist at the same receptor in the brain, while pharmacokinetic
interactions are noted when one drug affects the concentration
of another drug by influence on its absorption, distribution, and/
or elimination (Corrie and Hardman 2014; Zaccara and Perucca
2014). To determine the kinds of pharmacological interactions
occurred between PTE and CZP, CBZ and OXC, we evaluated
serum and total brain concentration of these antiepileptic drugs.
Our study revealed that the enhancement of the anticonvulsant
activity of CBZ and OXC resulted from the increase in both
serum and total brain concentrations of these drugs, which sug-
gests that noted interactions were pharmacokinetic in nature,
although the pharmacodynamic interactions might not be
completely excluded. Contrary to CBZ and OXC, PTE did not
change serum and total brain concentration of CZP, which indi-
cates that interaction between these two drugs might have phar-
macodynamic character. This kind of interaction might be desir-
able in clinical practice because it enables to enhance therapeutic
activity of drug without a need for using its higher doses.
We could hypothesize that pharmacokinetic interactions be-
tween PTE and other drugs, including antiepileptic drugs, i.e.,
CBZ and OXC, might also occur in the clinical practice. It was
noted that PTE is able to affect the activity of cytochrome P450
enzyme system which plays an important role in phase I me-
tabolism of many drugs and xenobiotics and catalyzes mainly
their oxidative metabolism, i.e., it inhibited CYP1A1,
CYP1A2, CYP2C8, and CYP3A4 (Albassam and Frye 2019;
Hyrsova et al. 2019; Mikstacka et al. 2007). Hyrsova et al.
(2019) reported that PTE inhibited CYP3A4 activity with the
inhibitory constant (Ki) lower than 10μM,while Albassam and
Frye (2019) detected that concentration of PTE that results in
50% inhibition (IC50) of CYP2C8 activity is less than 20 μM.
Although the content of PTE in the diet might be too low to
affect cytochrome P450 activity, its supplementationmight lead
to a sufficient increase in its concentration in the body and
impact on the activity of these enzymes, which would lead to
pharmacological interactions with drugs (Albassam and Frye
2019; Hyrsova et al. 2019). Furthermore, our previous study
(Nieoczym et al. 2019) revealed that serum and brain concen-
tration of PTE after its administration at a dose of 50 mg/kg is
enough for the inhibition of cytochrome P450 isoenzymes in
mice (detailed data available in Nieoczym et al. 2019).
In humans, CBZ is metabolized to carbamazepine-10,11-
epoxide, and this reaction is catalyzed primarily by CYP3A4,
CYP2C8, and CYP3A5 isoenzymes (Kerr et al. 1994; Pearce
et al. 2008). Since PTE might influence the activity of both
CYP3A4 and CYP2C8 isoenzymes, pharmacokinetic interac-
tions between this compound and CBZ is also possible in
clinical practice.
Although OXC is structurally similar to CBZ, its metabolism
is different because it is rapidly reduced by cytosol aryl ketone
reductase to its 10-monohydroxy derivative—MHD, which is
next cleared by glucuronide conjugation. Glucuronidation, link-
age of glucuronic acid component of uridine diphosphate glu-
curonic acid (UDP) to substrate, is catalyzed by a family of
uridine 5′-diphospho-glucuronosyl transferases (UDP-
glucuronosyltransferases, UGTs) (May et al. 2003; Rowland
et al. 2013). It has been recently reported that PTE significantly
inhibited UGT1A6 activity with IC50 value of approximately
15μM(Albassam and Frye 2019). As in the case of cytochrome
P450 isoenzymes, supplementation of PTE in humans may lead
to inhibition of UGTs activity and pharmacokinetic interactions
(Albassam and Frye 2019).
Mechanism of antiepileptic drugs action is often related to
their influence on the different membrane ion channels, which
consequently affects neurons excitability. Among the
Table 2 Effect of PTE on serum
and total brain concentration of
CZP, CBZ and OXC
Treatment (mg/kg) Serum concentration Total brain concentration
A
CZP (0.04) 16.40 ± 2.12 (ng/ml) 4.45 ± 0.61 (ng/g tissue)
CZP (0.04) + PTE (100) 14.28 ± 1.20 (ng/ml) 4.40 ± 0.32 (ng/g tissue)
Student’s t test: p = 0.1977 Student’s t test: p = 0.4705
B
CBZ (5.9) 2.06 ± 0.10 (μg/ml) 3.72 ± 0.45 (μg/g tissue)
CBZ (5.9) + PTE (100) 2.41 ± 0.06 (μg/ml)** 5.45 ± 0.36 (μg/g tissue)**
Student’s t test: p = 0.0043 Student’s t test: p = 0.0039
C
OXC (9.02) 2.97 ± 0.19 (μg/ml) 3.46 ± 0.27 (μg/g tissue)
OXC (9.02) + PTE (100) 4.23 ± 0.46 (μg/ml)* 5.47 ± 0.58 (μg/g tissue)**
Student’s t test: p = 0.0104 Student’s t test: p = 0.0027
PTE, CZP, CBZ, and OXC were administered ip 30 min before the samples collection. Each experimental group
consisted of 10 mice. Results are presented as the mean ± SEM. Serum and brain concentrations of the studied
antiepileptic drugs were analyzed using the Student t test. *p < 0.05, **p < 0.01 vs. control (treated with antiep-
ileptic drug alone) group. CBZ carbamazepine, CZP clonazepam, OXC oxcarbazepine, PTE pterostilbene
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antiepileptic drugs which were investigated in our study, CBZ,
OXC, and TPMworkmainly by inhibiting sodium and calcium
channels (Lasoń et al. 2011). There are no studies concerning
influence of PTE on membrane channels activity, but studies of
RES revealed that it might inhibit some sodium and calcium
channels in neurons (Kim et al. 2005; Li et al. 2005). RES, the
structure of which is quite similar to PTE, was previously dem-
onstrated to activate the activity of large-conductance calcium-
activated potassium channels in different types of cells includ-
ing central neurons (Li et al. 2000; Wang et al. 2016). Whether
PTE exerts anticonvulsant effects on potassium channels re-
mains to be further explored. The above data suggest that the
interactions between PTE and the studied antiepileptic drugs
might be also related to the interaction with the same ion chan-
nels in the neuronal cell membranes, and therefore, pharmaco-
dynamic interactions of the studied stilbene with CBZ and
OXC are also possible. Detailed studies on the effects of PTE
on the respective ion channels activity are required.
Pharmacokinetic interactions are rather not desired in clin-
ical practice because drug accumulation in body tissues might
not only increase its therapeutic effect but, above all, might
potentiate its toxicity and lead to the appearance and/or en-
hancement of side effects. We noted attenuation of muscular
strength in mice administered with a combination of PTE and
CBZ, but other side effects are also possible. Furthermore, we
did not detect changes in the muscular strength and motor
coordination in mice co-treated with OXC and PTE; however,
we could not exclude the occurrence of other side effects, i.e.,
related to memory and/or concentration.
In conclusion, our data suggest that PTE might affect the
activity of some antiepileptic drugs. It enhanced the anticon-
vulsant effect of CZP as a result of pharmacodynamic inter-
actions, but in the case of CBZ and OXC, the increase in
anticonvulsant effect resulted from pharmacokinetic interac-
tions. However, the presence of pharmacokinetic interactions
does not exclude completely the presence of pharmacodynam-
ic interactions. Although our study was carried out inmice and
the results could not be directly transferred to humans, caution
should be taken in using PTE in combination with CBZ and
OXC. On the other hand, combination of PTE with CZP
might have beneficial therapeutic effects. Further studies are
required to explore the influence of PTE on the activity of
antiepileptic drugs and to evaluate both beneficial and harmful
effects of using PTE in patients with epilepsy.
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